Efficacy of Tocilizumab vs. NSAIDs in the Treatment of Juvenile Rheumatoid Arthritis

Article Sidebar

PDF
Published: Apr 18, 2022
DOI: https://doi.org/10.47191/ijmscrs/v2-i4-02
Keywords:
.

Main Article Content

Daniela I. Sánchez
School of Medicine, Autonomous University of Guadalajara, Guadalajara, Jalisco, Mexico
Paola L. Padilla
School of Medicine, Autonomous University of Guadalajara, Guadalajara, Jalisco, Mexico
Felix Osuna Gutierrez
School of Medicine, Autonomous University of Guadalajara, Guadalajara, Jalisco, Mexico
Giancarlo T. Ornelasa
School of Medicine, Autonomous University of Guadalajara, Guadalajara, Jalisco, Mexico
Flavio Humberto Ávalos
School of Medicine, Autonomous University of Guadalajara, Guadalajara, Jalisco, Mexico

Abstract

Tocilizumab is a humanized monoclonal antibody that binds to IL-6 receptors, both the soluble receptor (sIL-6R) and the one located in the cell membrane. In this way it blocks the molecular complex of the receptor and prevents cytokine signaling. It is a drug which has recently been approved by the FDA, several studies recently carried out at international level (USA, Japan, Europe) have demonstrated the great efficacy of tocilizumab in the treatment of juvenile rheumatoid arthritis.

Article Details

How to Cite
Daniela I. Sánchez, Paola L. Padilla, Felix Osuna Gutierrez, Giancarlo T. Ornelasa, & Flavio Humberto Ávalos. (2022). Efficacy of Tocilizumab vs. NSAIDs in the Treatment of Juvenile Rheumatoid Arthritis. International Journal of Medical Science and Clinical Research Studies, 2(4), 262–265. https://doi.org/10.47191/ijmscrs/v2-i4-02
Issue
Vol. 2 No. 4 (2022): Volume 02 Issue 04 April 2022
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. Diaz-Torne, C., Ortiz, M. D., Moya, P., Hernandez, M. V., Reina, D., Castellvi, I., . . . Vidal, S. (2018). The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab. Seminars in Arthritis and Rheumatism, 47(6), 757-764.

doi:10.1016/j.semarthrit.2017.10.022

II. Zhang X, Morcos P, Saito T, Terao K. Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis. Expert Review of Clinical Pharmacology. 2013;6(2):123-137.

III. Frampton J. Tocilizumab: A Review of Its Use in the Treatment of Juvenile Idiopathic Arthritis. Pediatric Drugs. 2013;15(6):515-531.

IV. Wakabayashi, H., Hasegawa, M., Nishioka, Y., Minami, Y., Nishioka, K., & Sudo, A. (2012). Clinical outcome in patients with rheumatoid arthritis switched to tocilizumab after etanercept or infliximab failure. Clinical Rheumatology, 32(2), 253-259. doi:10.1007/s10067-012-2118-

V. Armijo J, Mediavilla A, Florez Beledo J. Farmacología humana. 6th ed. Barcelona: Elsevier Health Sciences Spain - T; 2013.

VI. Longo; Fauci; Kasper; Hauser; Jameson; Loscalzo. Harrison Principios de Medicina Interna. 18ª edición. Nueva York: McGraw-Hill; 2012. Vol. 2

VII. Katzung B. Farmacología básica y clínica. 13th ed. México: McGrawHill; 2013.

VIII. Harris J, Kessler E, Verbsky J. Update on the Treatment of Juvenile Idiopathic Arthritis. Current Allergy and Asthma Reports. 2013;13(4):337-346.

IX. Md Yusof M, Emery P. Targeting Interleukin-6 in Rheumatoid Arthritis. Drugs. 2013;73(4):341-356.

Most read articles by the same author(s)